Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Foghorn TherapeuticsFHTX -2.19%67 3-Year EBITDA Growth Rate is 23.00% as of Jun. 2026, which is 93% above its 10-year median of 11.90. GuruFocus rates FHTX with a GF Score™ of 67/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,129 Biotechnology companies, Foghorn Therapeutics ranks better than 59.88% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Foghorn Therapeutics was 25.50% per year. The lowest was -25.70% per year. And the median was 11.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Foghorn Therapeutics 3-Year EBITDA Growth Rate Related Terms
FHTX vs NWBO, FATE, IMRX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Foghorn Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.00% mean?
Foghorn Therapeutics (FHTX) has a 3-Year EBITDA Growth Rate of 23.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Foghorn Therapeutics and its competitors. This is 93% above median its historical median of 11.90. According to the industry distribution chart, Foghorn Therapeutics ranks #453 out of 1129 companies in the Biotechnology industry, placing it in the top 40.1%.
Is Foghorn Therapeutics' 3-Year EBITDA Growth Rate too high?
Foghorn Therapeutics' current 3-Year EBITDA Growth Rate of 23.00% is 93% above median its 10-year median of 11.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Foghorn Therapeutics' value of 23.00% is 54.4% above this industry median. Based on the distribution chart, Foghorn Therapeutics ranks #453 out of 1129 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' 3-Year EBITDA Growth Rate compare to NWBO and FATE?
According to the Biotechnology industry distribution chart, Foghorn Therapeutics ranks #453 out of 1129 companies for 3-Year EBITDA Growth Rate. This puts Foghorn Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Foghorn Therapeutics' value of 23.00% is 54.4% above this benchmark. While the company's 10-year median is 11.90 vs. the industry median of 14.90, Foghorn Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foghorn Therapeutics's current 3-Year EBITDA Growth Rate of 23.00% is 54.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Foghorn Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foghorn Therapeutics's current 3-Year EBITDA Growth Rate is 23.00%, which is 93% above median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.69 — trading 25.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 23.00%, which is 93% above median its 10-year median of 11.90 and 54.4% above the Biotechnology industry median of 14.90. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current 3-Year EBITDA Growth Rate is 23.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foghorn Therapeutics (FHTX) Overvalued in 2026?
Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued.
The current stock price of $6.69 is trading 25.8% above its estimated GF Value™ of $5.32.
GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.
Key valuation signals for FHTX:
3-Year EBITDA Growth Rate: 23.00% (93% above median its 10-year median of 11.90)
GF Value™: $5.32 vs. price of $6.69 (25.8% above fair value)
Industry Position: 54.4% above the Biotechnology median (#453 of 1129)
No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score
Get the complete analysis for FHTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FHTX has been successfully added to your 
